Continuous Manufacturing Market is Set to Soar to USD 4,193 Million by 2035 with CAGR of 4.9%

Advances in manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step batch manufacturing processes to faster, and relatively more efficient continuous manufacturing
The continuous manufacturing market valued at USD 2,349 million in 2024, is project to reach USD 2,599 million in 2025 and USD 4,193 million by 2035, representing a CAGR of 4.9% during the forecast period 2025 to 2035.
For decades, pharmaceutical companies have been using batch processing method for drug manufacturing, wherein a specific quantity of a drug is produced through multiple sequential steps. However, batch processing / batch manufacturing of a drug substance or drug products can be slow and inefficient. As a result, drug developers have begun to adopt continuous manufacturing systems to streamline drug production process. Continuous manufacturing involves the production of pharmaceutical drug substance / drug products in a single run, while operating 24×7. In this process, the drug is developed from its base ingredients / raw materials and processed to the final product in one facility, without any hold time. This technique offers several advantages over traditional batch processing, which includes reduction in facility footprint (by 70%), reduction in operational and running costs (by 40-50%) and easy scale up.
To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/continuous-manufacturing/request-quote.html
Further, the outbreak of COVID-19 pandemic fueled the growth of the global market of continuous manufacturing; this can be attributed to the fact that that traditional batch processing relies on complex supply chain to manufacture raw materials for API manufacturing. On the contrary, continuous manufacturing can easily accommodate scale-up and post-approval changes in drug production which is advantageous in case of drug shortages. Biden administration has supported increased funding of pharmaceutical continuous manufacturing technologies to overcome challenges associated with pharmaceutical supply chain. Such developments will support the continuous manufacturing market growth.
To request a sample copy / brochure of this report, please visit:
https://www.rootsanalysis.com/reports/continuous-manufacturing/request-sample.html
Presently, close to 60 manufacturers have adopted continuous manufacturing for single or multiple unit operations. Various types of biologics, including antibodies, enzymes, proteins / peptides, vaccines and viral vectors can be synthesized utilizing continuous manufacturing technique. It is worth noting that close to 75% of the continuous biologic manufacturers offer contract manufacturing services for continuous manufacturing of the above mentioned biologics.
Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/continuous-manufacturing/308.html

Majority of these manufacturers are headquartered in North America (~40%) followed by Europe and Asia Pacific. Most of the continuous biologic manufacturers possess the expertise for continuous cell culturing (86%); this can be attributed to the fact that upstream bioprocessing is comparatively more established, owing to the extensive usage of perfusion technologies by the biologic manufacturers from past two decades. It is worth noting that presently antibodies are the most common biologic for which continuous bioprocessing is currently being adopted.

Contact Details for Roots Analysis
Chief Executive: Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.